Finance

Lists
002773:SHE
Chengdu Kanghong Pharma Grp Co Ltd
CNÂ¥20.30
+0.25%
(+0.050) 1D
Sep 4, 3:04:09 PM GMT+8  ·   CNY
All symbols
SymbolPriceChange% Change
Generating top insights for 002773...
Open
CNÂ¥20.27
High
CNÂ¥20.53
Low
CNÂ¥20.23
Mkt. cap
18.71B
Avg. vol.
8.06M
Volume
4.71M
Dividend
3.45%
Quarterly dividend
CNÂ¥0.18
Ex-dividend date
Jun 9, 2026
P/E ratio
18.80
52-wk high
CNÂ¥41.65
52-wk low
CNÂ¥18.97
EPS
CNÂ¥1.08
Shares outstanding
921.33M
No. of employees
4K
Open
CNÂ¥20.27
High
CNÂ¥20.53
Low
CNÂ¥20.23
Mkt. cap
18.71B
Avg. vol.
8.06M
Volume
4.71M
Dividend
3.45%
Quarterly dividend
CNÂ¥0.18
Ex-dividend date
Jun 9, 2026
P/E ratio
18.80
52-wk high
CNÂ¥41.65
52-wk low
CNÂ¥18.97
EPS
CNÂ¥1.08
Shares outstanding
921.33M
No. of employees
4K
Profile
Chengdu Kanghong Pharmaceutical Group Co., Ltd. is a publicly traded pharmaceutical company based in the province of Sichuan, China. It was founded in 1996 and researches, develops, manufactures, and distributes medicines for ophthalmic, central nervous, digestive and endocrine systems. The company is listed on the Shenzhen stock exchange with a market capitalization at around $6 billion. As of May 2021, the company had 18 drugs on the market including Lumitin. Additional products include Songling xuemaikang capsules, Keluoxin capsules, Xinluona, Bolexin and Bosiqing, Yitaning, Shugan Jieyu, Danshu, and Yiqing. Kanghong also currently has 13 subsidiaries in China, Israel, and the United States. Wikipedia
About Chengdu Kanghong Pharma Grp Co Ltd
CEO-
Employees4.47K
FoundedOct 3, 1996
Headquarters-
SectorPharmaceutical industry
Websitecnkh.com
Previous reportsAll values in CNY
Loading Previous Earnings...
Income statement
Revenue
Net income
All values in CNY
Sep 2025
Dec 2025
Mar 2026
Jun 2026
Revenue
1.17B
961.27M
1.05B
1.13B
Cost of goods sold
103.16M
116.91M
118.65M
132.03M
Cost of revenue
103.16M
116.91M
118.65M
132.03M
Research and development expenses
119.54M
198.94M
86.77M
138.57M
Total research and development expenses
-
-
-
-
Selling, general, and admin expenses
595.28M
521.75M
478.88M
554.55M
Operating expense
697.02M
764.40M
582.81M
717.78M
Total operating expenses
800.18M
881.31M
701.46M
849.80M
Operating income
370.02M
79.96M
345.02M
282.88M
Other non operating income
-19.53M
19.27M
-1.04M
-1.54M
EBT including unusual items
355.99M
147.66M
358.51M
301.88M
EBT excluding unusual items
364.66M
135.96M
356.39M
306.28M
Income tax expense
56.73M
23.28M
55.31M
50.13M
Effective tax rate
15.94%
15.77%
15.43%
16.61%
Other operating expenses
-17.83M
43.89M
16.62M
23.18M
Net income
303.21M
130.06M
307.48M
257.26M
Net profit margin
25.91%
13.53%
29.38%
22.71%
Earnings per share
-
-
-
-
Interest and investment income
14.20M
36.91M
12.63M
24.92M
Interest expense
-
-
-
-
Net interest expenses
14.20M
36.91M
12.63M
24.92M
Depreciation and amortization charges
-
-
-
-
EBITDA
427.31M
139.05M
404.11M
345.15M
Gain or loss from assets sale
3.47K
-9.78K
-
61.06K
AI content may include mistakes. Learn more
Google apps